Livzon Pharmaceutical Group Inc.

000513

CNE0000002Y8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-07-15 EDT			5-day change	1st Jan Change
35.41 ^CNY	-1.17%		-1.39%	+1.14%

06-28	Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) for 2023, Payable on 08 July 2024	CI
06-28	Livzon Pharmaceutical Group Cancels Repurchased Shares	MT

Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) for 2023, Payable on 08 July 2024

June 28, 2024 at 03:32 pm

Livzon Pharmaceutical Group Inc. announced the final cash dividend (A shares) (tax included) for 2023 of CNY 13.50000000 per share. The dividend will be payable on 08 July 2024 with Record date of 05 July 2024 and Ex-date of 08 July 2024.

Latest news about Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc. Announces the Final Cash Dividend (A Shares) for 2023, Payable on 08 July 2024	06-28	CI
Livzon Pharmaceutical Group Cancels Repurchased Shares	06-28	MT
India's Biocon seeks partner to test generic Wegovy, Ozempic in China	06-20	RE
Livzon Pharmaceutical Group Inc. Approves Cash Dividend for 2023	06-17	CI
Second Chinese drugmaker seeks approval for Ozempic generic	06-13	RE
Sihuan Pharma Subsidiary Licenses Fadanafil Drug to Livzon Pharmaceutical Unit	06-13	MT
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic	06-05	RE
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China	06-05	RE
Livzon Pharmaceutical Cancels 5.3 Million Share Options	05-27	MT
Livzon Pharmaceutical Group Cancels Share Options	05-14	MT
Livzon Pharmaceutical Declares Final Dividend for 2023	05-13	MT
Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection	04-26	CI
Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%	04-24	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-23	CI
Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.	04-02	CI
Livzon Pharma's 2023 Profit Rises 2%; Revenue Falls 2%	03-29	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024	03-28	CI
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug	02-23	MT
Livzon Group Livzon Medical Research Centre Receives Notice of Drug Clinical Trial Approval Issued by China National Medical Products Administration	02-22	CI
Livzon Pharma Gets Nod to Trial Weight Management Drug	02-05	MT
Livzon Pharmaceutical Appoints Former Joincare Exec as Vice President	01-30	MT
Livzon Pharmaceutical Group Inc. commences an Equity Buyback Plan for CNY 600 million worth of its shares, under the authorization approved on Decemeber 19, 2023.	01-18	CI
Livzon Pharma Recognizes Credit, Asset Impairments	01-10	MT
Livzon Pharmaceutical to Continue Getting Services from Joincare Pharmaceutical	01-02	MT

Chart Livzon Pharmaceutical Group Inc.

Duration

Period

More charts

Company Profile

LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Livzon Pharmaceutical Group Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

35.41 CNY

Average target price

41.14 CNY

Spread / Average Target

+16.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIVZON PHARMACEUTICAL GROUP INC.	+1.14%	3.99B
ELI LILLY AND COMPANY	+61.96%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.69%	359B
MERCK & CO., INC.	+14.92%	325B
ABBVIE INC.	+9.06%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.75%	177B
PFIZER, INC.	+2.43%	165B

Other Pharmaceuticals